Novartis (NVS) Stock
NEW YORK STOCK EXCHANGE, INC. · NVS
139.78
Fundamentals
Market cap
$267.85B
Price / Earnings ratio
20.7x
Price / Sales ratio
4.7x
Price / Book ratio
6.3x
Return on assets
0.1%
Ex-Dividend date
11 Mar 2026
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
2.2%
Debt / Equity ratio
N/A
Latest news
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
SectorHealthcare
IndustryDrug Manufacturers - General
Employees75,267
CEODr. Vasant Narasimhan M.D.
IPO DateNov 18, 1991
HeadquartersBasel, Switzerland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer | 1976 |
| Mr. Victor Bulto | President of US | 1978 |
| Dr. Patrick Horber M.D. | President of International | 1970 |
| Mr. Mukul Mehta | Chief Financial Officer | 1973 |
| Dr. Steffen Lang Ph.D. | President of Operations | 1967 |
| Paul Penepent | Head of Group Financial Reporting and Accounting | — |
| Ms. Sloan Simpson | Global Head of Investor Relations | — |
| Ms. Karen L. Hale | Chief Legal & Compliance Officer | 1968 |
| Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 1968 |
| Mr. Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research | — |
Fundamentals
Valuation
Market cap$267.85B
Price-to-sales ratio4.65
Price-to-book value6.35
Price-earnings ratio20.70
Return on Equity32.00%
Return on Sales0.30%
Return on Assets0.12%
PEG ratio2.87
Earnings Per Share
Earnings Per Share$6.66
Income Statement
Average volume2,355,343
EBITDA$28.03B
1 year high (52w)$170.46
1 year low (52w)$121.57
Dividend
Ex dividend date11 Mar 2026
Dividend amount$0.00
Dividend yield2.20%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



